Page 102 - JCTR-11-5

Journal of Clinical and

Translational Research

ORIGINAL ARTICLE
Association between serum uric acid and

prostate cancer risk: The modifying role of CTGF
genotype

1
Randi Chen * , Timothy A. Donlon 1,2 , Richard C. Allsopp 3 ,
Brian J. Morris 1,4 , Bradley J. Willcox 1,5† , and Kamal H. Masaki 1,5†
1 Department of Research, Kuakini Japan-Hawaii Cancer Study, Kuakini Honolulu Heart Program,
Center of Biomedical Research Excellence (COBRE) for Clinical and Translational Research on
Aging, Kuakini Medical Center, Honolulu, Hawaii, United States of America
2 Department of Cell and Molecular Biology, University of Hawaii, Honolulu, Hawaii, United States
of America
3 Department of Anatomy, Biochemistry and Physiology, Institute for Biogenesis Research, University
of Hawaii, Honolulu, Hawaii, United States of America
4 School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia
5 Department of Geriatric Medicine, University of Hawaii, Honolulu, Hawaii, United States of America

† These authors contributed equally
to this work.
Abstract
*Corresponding author:
Randi Chen Background: The role of uric acid in prostate cancer risk remains uncertain, with
(r.chen@kuakini.org)
evidence suggesting both carcinogenic and protective effects. Genetic factors may be
Citation: Chen R, Donlon TA, key modifiers of this association. Objective: This study aimed to determine whether
Allsopp RC, Morris BJ, Willcox BJ,
Masaki KH. Association between the relationship between uric acid and prostate cancer risk differs by the rs9399005
serum uric acid and prostate genotype of connective tissue growth factor (CTGF). Methods: We examined 6,259
cancer risk: The modifying role of Japanese-American men in Hawaii, cancer-free at baseline (1965–1968, ages 45–68),
CTGF genotype. J Clin Transl Res.
2025;11(5):96-105. who were followed for incident prostate cancer until 1999. Hyperuricemia was
doi: 10.36922/JCTR025260029 defined as serum uric acid ≥7.0 mg/dL. CTGF genotypes were classified as common
Received: June 23, 2025 allele homozygotes (CC) or minor allele carriers (T). Cox proportional hazards
models estimated hazard ratios (HRs), adjusting for age and potential confounders.
Revised: September 16, 2025 Results: During a median follow-up of 29.7 years, 285 prostate cancer cases were
Accepted: September 30, 2025 identified. A significant interaction between CTGF and hyperuricemia was observed.
Published online: October 15, Among men with the CTGF–T genotype, hyperuricemia was not associated with risk
2025 (HR = 0.77, 95% confidence interval [CI]: 0.51–1.17). In contrast, among CTGF–CC
homozygotes, hyperuricemia was linked to a higher risk (HR = 1.91, 95% CI: 1.21–2.99).
Copyright: 2025 Author(s).
This is an open-access article Men with both the CTGF–CC genotype and hyperuricemia had a higher risk (HR = 1.72,
distributed under the terms of the 95% CI: 1.17–2.54) compared with all other subjects. Conclusion: The association
Creative Commons AttributionNon- between uric acid and prostate cancer varied by CTGF genotype. Hyperuricemia
Commercial 4.0 International (CC
BY-NC 4.0), which permits all increased risk among CTGF–CC homozygotes, whereas a nonsignificant protective
non-commercial use, distribution, effect was seen among T allele carriers. Relevance to patients: Monitoring and
and reproduction in any medium, lowering serum uric acid may help reduce prostate cancer risk in men with the
provided the original work is
properly cited. CTGF–CC genotype.
Publisher’s Note: AccScience
Publishing remains neutral with Keywords: CTGF; Connective tissue growth factor; Uric acid; Hyperuricemia;
regard to jurisdictional claims in
published maps and institutional Gene-environment interaction; Prostate cancer
affiliations.

Volume 11 Issue 5 (2025) 96 doi: 10.36922/JCTR025260029